BTIG reiterates Buy rating and $178 target for Nektar Therapeutics
BTIG reiterated a Buy rating on Nektar Therapeutics and set a $178.00 price target.
Story updates
05:23:53 PM UTC
SquawkNews
Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG